Chemotherapy principles in the treatment of prostatic cancer.

Abstract

The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria. Although complete regressions remain exceptional, a number of agents, eg, doxorubicin and cisplatin have been shown to be effective in the treatment of this disease. So far, combinations of effective agents with or without concomitant hormone therapy have not proven to be more effective than single agents. Androgen priming has considerable theoretical appeal and deserves further consideration. A higher effectiveness of chemotherapeutic agents might be obtained by linkage to various carriers. Estramustine phosphate is an example of such a complex that has a cytotoxic effect in test systems in which estrogen has no effect and in patients with hormone-refractory prostatic cancer. The use of hormonal and other carriers that could increase the specificity of chemotherapeutic agents deserves extensive exploration.

• Authors: I Könyves, J Müntzing, M Rozencweig
• Journal: The Prostate (Prostate) Vol. 5 Issue 1 Pg. 55-62 ( 1984) ISSN: 0270-4137 [Print] United States
• PMID: 6364076 (Publication Type: Journal Article, Review)

Chemical References

• Estradiol Congeners
• Testosterone Congeners
• Doxorubicin
• Cyclophosphamide
• Cisplatin
• Fluorouracil
• Carmustine
• Methotrexate

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carmustine (administration & dosage)
• Castration
• Cisplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Evaluation, Preclinical
• Estradiol Congeners (administration & dosage)
• Fluorouracil (administration & dosage)
• Humans
• Male
• Methotrexate (administration & dosage)
• Prostatic Neoplasms (drug therapy)
• Rats
• Structure-Activity Relationship
• Testosterone Congeners (administration & dosage)